Splenectomy
Splenectomy - Related Videos
08:34
Robot-assisted Partial Splenectomy
0 Views •
2026
This protocol describes a robot-assisted partial splenectomy for a benign splenic tumor. The robotic approach optimizes spleen preservation by enhancing surgical precision, minimizing blood loss, and improving postoperative outcomes. Key surgical steps include meticulous splenic hilum dissection, selective vascular ligation, intraoperative ultrasonography, and controlled parenchymal transection.
03:49
Application of Microwave Ablation in Laparoscopic Partial Splenectomy
0 Views •
Cited by 2 •
2024
The use of laparoscopic partial splenectomy has been limited due to the high risk of bleeding during surgery. Therefore, we introduce a laparoscopic method combined with microwave ablation to solve the problem of intraoperative bleeding.
04:00
Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension
0 Views •
Cited by 2 •
2024
With the rapid advancement of laparoscopic techniques, the minimally invasive benefits of laparoscopic splenectomy combined with pericardial devascularization have become increasingly evident. In this context, we present a protocol for performing laparoscopic splenectomy alongside pericardial devascularization to treat hypersplenism and esophageal variceal hemorrhage resulting from portal hypertension.
02:09
Application of Laparoscopic Partial Splenectomy with Total Blood Flow Occlusion in Benign Splenic Lesions
0 Views •
Cited by 1 •
2024
In this study, we describe an intraoperative hemorrhage control technique for laparoscopic partial splenectomy, improving spleen resection's safety and precision.
04:42
An Ex Vivo Technique to Generate Tumor-Specific Chimeric Antigen Receptor T Cells
0 Views •
2025
This video demonstrates a technique for the ex vivo generation of tumor antigen-specific chimeric antigen receptor (CAR) T cells. Retroviral vectors carrying transgenic RNA are mixed with spleen cells in a medium supplemented with interleukin-2 to promote T-cell survival and proliferation. The mixture is then transferred to a plate coated with recombinant human fibronectin fragments and centrifuged to facilitate the fusion of the virus with the cell, allowing the RNA to integrate into the host...
FAQs
After splenectomy, the body has reduced ability to clear particular bacteria from the bloodstream because it no longer has the spleen’s filtering and immune-defense functions. This change does not mean infection is inevitable, but it makes preventive planning important. Vaccination and an individualized infection-prevention plan therefore become central parts of long-term follow-up.
The spleen contributes to platelet regulation, so removing it can lead to thrombocytosis, meaning an increased platelet count. This is a recognized postoperative issue rather than a direct measure of whether the operation achieved its original goal. Clinical follow-up includes monitoring for this and other complications, allowing care teams to identify changes after recovery begins.
Accessory splenic tissue matters because removing the main spleen may not account for all splenic tissue present. The overview specifically notes that surgeons may evaluate for accessory tissue during the operation. This assessment is part of operative planning and helps the surgical team understand whether additional splenic tissue should be considered when completing the intended procedure.
Both approaches require control of the spleen’s blood supply and separation from surrounding tissues, but they represent different operative routes. The overview identifies open and laparoscopic surgery as the principal approaches without assigning one universally preferred option. The choice is therefore part of procedure planning and is considered in relation to the clinical situation being treated.
Potential indications include traumatic splenic injury, splenic enlargement, selected blood disorders, and certain tumors. The operation is not presented as the first response to every such condition; the overview specifies that some tumors are treated surgically when other therapies are insufficient. Thus, the underlying diagnosis and adequacy of alternatives shape the decision to operate.
Follow-up should address infection prevention and blood-count changes. Vaccination planning helps respond to the reduced clearance of particular bacteria, while monitoring can detect thrombocytosis and other postoperative complications. These measures extend beyond the operation itself because removal changes immune defense and platelet regulation. Ongoing planning is therefore part of the treatment pathway, not an optional add-on.